Loading...

Shanghai Haohai Biological Technology

DB:5HB
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5HB
DB
HK$9B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Shanghai Haohai Biological Technology Co., Ltd. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Shanghai Haohai Biological Technology has significant price volatility in the past 3 months.
5HB Share Price and Events
7 Day Returns
-0.2%
DB:5HB
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
24%
DB:5HB
-10.2%
DE Biotechs
-6%
DE Market
5HB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Shanghai Haohai Biological Technology (5HB) -0.2% 19.7% 52.3% 24% 30.5% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 5HB outperformed the Biotechs industry which returned -10.2% over the past year.
  • 5HB outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
5HB
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Shanghai Haohai Biological Technology's competitors could be found in our database.

5HB Value

 Is Shanghai Haohai Biological Technology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Shanghai Haohai Biological Technology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Shanghai Haohai Biological Technology.

DB:5HB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:5HB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 25%) (0.45%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:5HB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Shanghai Haohai Biological Technology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:5HB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8%)
2019 277.71 Est @ 18.29% 257.15
2020 313.46 Est @ 12.87% 268.76
2021 341.93 Est @ 9.08% 271.47
2022 363.89 Est @ 6.42% 267.52
2023 380.51 Est @ 4.57% 259.02
2024 392.93 Est @ 3.26% 247.68
2025 402.18 Est @ 2.35% 234.74
2026 409.08 Est @ 1.72% 221.09
2027 414.27 Est @ 1.27% 207.32
2028 418.24 Est @ 0.96% 193.81
Present value of next 10 years cash flows CN¥2,428.54
DB:5HB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CN¥418.24 × (1 + 0.23%) ÷ (8% – 0.23%)
CN¥5,396.78
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥5,396.78 ÷ (1 + 8%)10
CN¥2,500.81
DB:5HB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥2,428.54 + CN¥2,500.81
CN¥4,929.36
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥4,929.36 / 160.05
CN¥278.82
DB:5HB Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:6826)
1.169
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥30.8 x 1.169
HK$36.01
Non-primary Listing Adjustment Factor 1 share in DB:5HB represents 0.11046x of SEHK:6826
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.11046x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 36.01 x 0.11046
€3.98
Value per share (EUR) From above. €3.98
Current discount Discount to share price of €6.53
= -1 x (€6.53 - €3.98) / €3.98
-64.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Shanghai Haohai Biological Technology is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Shanghai Haohai Biological Technology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Shanghai Haohai Biological Technology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5HB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CNY CN¥2.59
SEHK:6826 Share Price ** SEHK (2019-04-18) in HKD HK$59.15
SEHK:6826 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.855 CN¥50.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Shanghai Haohai Biological Technology.

DB:5HB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:6826 Share Price ÷ EPS (both in CNY)

= 50.59 ÷ 2.59

19.53x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shanghai Haohai Biological Technology is good value based on earnings compared to the Europe Biotechs industry average.
  • Shanghai Haohai Biological Technology is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Shanghai Haohai Biological Technology's expected growth come at a high price?
Raw Data
DB:5HB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 19.53x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Shanghai Haohai Biological Technology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Shanghai Haohai Biological Technology's assets?
Raw Data
DB:5HB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CNY CN¥22.57
SEHK:6826 Share Price * SEHK (2019-04-18) in HKD HK$59.15
SEHK:6826 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.855 CN¥50.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:5HB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:6826 Share Price ÷ Book Value per Share (both in CNY)

= 50.59 ÷ 22.57

2.24x

* Primary Listing of Shanghai Haohai Biological Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shanghai Haohai Biological Technology is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Shanghai Haohai Biological Technology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Shanghai Haohai Biological Technology has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5HB Future Performance

 How is Shanghai Haohai Biological Technology expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.6%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Shanghai Haohai Biological Technology expected to grow at an attractive rate?
  • Shanghai Haohai Biological Technology's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Shanghai Haohai Biological Technology's earnings growth is expected to exceed the Germany market average.
  • Shanghai Haohai Biological Technology's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5HB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5HB Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 17.6%
DB:5HB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 18.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5HB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5HB Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,741 1
2020-12-31 2,201 1
2019-12-31 1,819 1
DB:5HB Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2018-12-31 1,546 415
2018-09-30 1,523 411
2018-06-30 1,501 404 408
2018-03-31 1,423 374 390
2017-12-31 1,345 343 372
2017-09-30 1,214 330 351
2017-06-30 1,083 317 329
2017-03-31 967 286 317
2016-12-31 851 254 305
2016-09-30 787 245 295
2016-06-30 724 235 284
2016-03-31 694 252 279

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Shanghai Haohai Biological Technology's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
  • Shanghai Haohai Biological Technology's revenue is expected to grow by 18.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5HB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HB Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 4.45 4.45 4.45 1.00
2020-12-31 3.70 3.70 3.70 1.00
2019-12-31 3.06 3.06 3.06 1.00
DB:5HB Past Financials Data
Date (Data in CNY Millions) EPS *
2018-12-31 2.59
2018-09-30 2.57
2018-06-30 2.55
2018-03-31 2.44
2017-12-31 2.33
2017-09-30 2.19
2017-06-30 2.06
2017-03-31 1.98
2016-12-31 1.91
2016-09-30 1.84
2016-06-30 1.77
2016-03-31 1.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Shanghai Haohai Biological Technology is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Shanghai Haohai Biological Technology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Shanghai Haohai Biological Technology has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5HB Past Performance

  How has Shanghai Haohai Biological Technology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Shanghai Haohai Biological Technology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Shanghai Haohai Biological Technology has delivered over 20% year on year earnings growth in the past 5 years.
  • Shanghai Haohai Biological Technology's 1-year earnings growth is less than its 5-year average (11.3% vs 20.4%)
  • Shanghai Haohai Biological Technology's earnings growth has not exceeded the Europe Biotechs industry average in the past year (11.3% vs 18.2%).
Earnings and Revenue History
Shanghai Haohai Biological Technology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5HB Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,545.82 414.54 737.49 95.37
2018-09-30 1,523.31 411.30 714.70 89.33
2018-06-30 1,500.81 408.06 691.92 83.28
2018-03-31 1,422.83 390.24 650.38 79.81
2017-12-31 1,344.86 372.42 608.84 76.33
2017-09-30 1,214.10 350.86 555.42 67.49
2017-06-30 1,083.35 329.31 502.00 58.65
2017-03-31 967.25 317.18 439.98 52.95
2016-12-31 851.16 305.05 377.95 47.26
2016-09-30 787.45 294.58 357.61 43.73
2016-06-30 723.74 284.11 337.27 40.21
2016-03-31 693.83 278.79 319.13 37.73
2015-12-31 663.92 273.47 300.98 35.25
2015-09-30 630.34 258.16 277.97 31.84
2015-06-30 596.77 242.84 254.97 28.43
2015-03-31 556.35 213.21 245.56 27.45
2014-12-31 515.94 183.58 236.15 26.46
2014-09-30 482.45 168.99 221.26 27.30
2014-06-30 448.96 154.40 206.36 28.14
2014-03-31 425.02 147.96 191.95 25.83
2013-12-31 401.09 141.52 177.54 23.52
2012-12-31 303.07 113.94 108.81 17.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Shanghai Haohai Biological Technology has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Shanghai Haohai Biological Technology used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Shanghai Haohai Biological Technology has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Shanghai Haohai Biological Technology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Shanghai Haohai Biological Technology has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5HB Health

 How is Shanghai Haohai Biological Technology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Shanghai Haohai Biological Technology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Shanghai Haohai Biological Technology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Shanghai Haohai Biological Technology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Shanghai Haohai Biological Technology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 62.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Shanghai Haohai Biological Technology Company Filings, last reported 3 months ago.

DB:5HB Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3,835.45 36.66 1,438.41
2018-09-30 3,835.45 36.66 1,438.41
2018-06-30 3,546.37 39.00 1,398.73
2018-03-31 3,546.37 39.00 1,398.73
2017-12-31 3,366.71 37.48 1,855.06
2017-09-30 3,366.71 37.48 1,855.06
2017-06-30 3,140.51 25.17 1,804.16
2017-03-31 3,140.51 25.17 1,804.16
2016-12-31 2,985.86 26.67 2,112.89
2016-09-30 2,985.86 26.67 2,112.89
2016-06-30 2,731.62 0.00 2,212.48
2016-03-31 2,731.62 0.00 2,212.48
2015-12-31 2,665.43 0.00 2,190.13
2015-09-30 2,665.43 0.00 2,190.13
2015-06-30 2,530.26 0.00 2,071.73
2015-03-31 2,530.26 0.00 2,071.73
2014-12-31 594.16 0.00 195.23
2014-09-30 594.16 0.00 195.23
2014-06-30 612.21 0.00 204.82
2014-03-31 612.21 0.00 204.82
2013-12-31 530.58 0.00 204.23
2012-12-31 389.06 0.00 167.82
  • Shanghai Haohai Biological Technology's level of debt (1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1% today).
  • Debt is well covered by operating cash flow (1102.9%, greater than 20% of total debt).
  • Shanghai Haohai Biological Technology earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Shanghai Haohai Biological Technology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Shanghai Haohai Biological Technology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5HB Dividends

 What is Shanghai Haohai Biological Technology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.99%
Current annual income from Shanghai Haohai Biological Technology dividends. Estimated to be 1.85% next year.
If you bought €2,000 of Shanghai Haohai Biological Technology shares you are expected to receive €20 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Shanghai Haohai Biological Technology's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • Shanghai Haohai Biological Technology's dividend is below the markets top 25% of dividend payers in Germany (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5HB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5HB Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 1.11 1.00
2020-12-31 0.93 1.00
2019-12-31 0.77 1.00
DB:5HB Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-03-14 0.500 1.104
2019-02-01 0.500 1.280
2018-03-26 0.500 1.230
2017-06-23 0.500 1.517
2016-04-14 0.400 1.204
2016-03-21 0.400 1.072

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Shanghai Haohai Biological Technology has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Shanghai Haohai Biological Technology only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Shanghai Haohai Biological Technology's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (5.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4x coverage).
X
Income/ dividend checks
We assess Shanghai Haohai Biological Technology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Shanghai Haohai Biological Technology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Shanghai Haohai Biological Technology has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5HB Management

 What is the CEO of Shanghai Haohai Biological Technology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jianying Wu
COMPENSATION CN¥1,246,000
AGE 54
TENURE AS CEO 8.8 years
CEO Bio

Dr. Jianying Wu has been General Manager and Executive Director of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010. Mr. Wu worked as a surgeon at the General Surgery Department of the Second Affiliated Hospital of the Second Military Medical University. from 1991 to 1999. He worked at Shanghai Huayuan Life Sciences Research and Development Company Limited. (Shanghai Huayuan) from March 2003 to February 2004, at the Shanghai branch of China Huayuan Life Industry Limited. from February 2004 to May 2005 at Cinkate Pharmaceutical and Chemical Intermediates (Shanghai) Company Limited a company principally engaged in development and production of pharmaceutical and chemical intermediates, as well as selling its own products and providing relevant technical advisory services from May 2005 to July 2007. He served as the general manager at Haohai Limited from July 2007 to June 2010. He has been acting as the general manager at Shanghai Qisheng since August 2010, the general manager and executive director at Shanghai Likangrui since December 2010 and also the Chairman of Shanghai Baiyue since January 2015. He has been the Chairman of New Industries since November 2016 and the Executive director of Zhuhai Eye Good in December 2016. He served as vice chairman of Henan Universe since August 2015 and Executive Director of Haohai Development since February 2016, the Director of Haohai Healthcare Holdings (Cayman) Co., Ltd., a subsidiary of our Company since May 2016, the director of Haohai Healthcare Holdings (BVI) Co., Ltd. since August 2016, a subsidiary of our Company since May 2016. He serves as Director and general manager since July 2010 and was redesignated as an executive Director on 7 December 2014. He served as the Director of Haohai Healthcare since July 2015. Mr. Wu obtained a master's degree in clinical medicine from the Second Military Medical University in June 1997 and the practicing doctor qualification in the PRC in May 1999.

CEO Compensation
  • Jianying's compensation has increased by more than 20% in the past year.
  • Jianying's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Shanghai Haohai Biological Technology management team in years:

6.6
Average Tenure
42.5
Average Age
  • The average tenure for the Shanghai Haohai Biological Technology management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yongtai Hou

TITLE
Chairman
COMPENSATION
CN¥1M
AGE
56
TENURE
8.8 yrs

Jianying Wu

TITLE
GM & Executive Director
COMPENSATION
CN¥1M
AGE
54
TENURE
8.8 yrs

Minjie Tang

TITLE
CFO & Executive Director
COMPENSATION
CN¥951K
AGE
43
TENURE
2.3 yrs

Yiyi Chen

TITLE
Executive Director
COMPENSATION
CN¥775K
AGE
36
TENURE
8.8 yrs

Ming Huang

TITLE
Joint Company Secretary & Executive Director
COMPENSATION
CN¥695K
AGE
42
TENURE
4.4 yrs

Ming King Chiu

TITLE
Joint Company Secretary
AGE
40
TENURE
4.4 yrs
Board of Directors Tenure

Average tenure and age of the Shanghai Haohai Biological Technology board of directors in years:

8.8
Average Tenure
50
Average Age
  • The tenure for the Shanghai Haohai Biological Technology board of directors is about average.
Board of Directors

Yongtai Hou

TITLE
Chairman
COMPENSATION
CN¥1M
AGE
56
TENURE
8.8 yrs

Jianying Wu

TITLE
GM & Executive Director
COMPENSATION
CN¥1M
AGE
54
TENURE
8.8 yrs

Minjie Tang

TITLE
CFO & Executive Director
COMPENSATION
CN¥951K
AGE
43
TENURE
2.2 yrs

Yiyi Chen

TITLE
Executive Director
COMPENSATION
CN¥775K
AGE
36
TENURE
8.8 yrs

Ming Huang

TITLE
Joint Company Secretary & Executive Director
COMPENSATION
CN¥695K
AGE
42
TENURE
8.8 yrs

Jie You

TITLE
Non Executive Director
AGE
55
TENURE
8.8 yrs

Hongbo Shen

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
39
TENURE
4.5 yrs

Yuanxu Li

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
51
TENURE
8.3 yrs

Qin Zhu

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥84K
AGE
54
TENURE
4.5 yrs

Yuanzhong Liu

TITLE
Chairman of the Supervisory Committee
AGE
49
TENURE
8.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Apr 19 Sell Franklin Resources, Inc. Company 10. Apr 19 10. Apr 19 -48,400 €6.24 €-302,241
11. Apr 19 Sell Matthews International Capital Management, LLC Company 09. Apr 19 09. Apr 19 -39,900 €6.09 €-243,185
19. Mar 19 Sell Franklin Resources, Inc. Company 15. Mar 19 15. Mar 19 -175,200 €5.66 €-991,366
16. Jan 19 Sell Matthews International Capital Management, LLC Company 14. Jan 19 14. Jan 19 -39,500 €4.12 €-162,834
17. Dec 18 Buy Minjie Tang Individual 14. Dec 18 14. Dec 18 2,000 €4.19 €8,389
21. Nov 18 Sell Matthews International Capital Management, LLC Company 19. Nov 18 19. Nov 18 -43,000 €4.97 €-213,916
30. Oct 18 Buy Minjie Tang Individual 25. Oct 18 25. Oct 18 2,000 €4.82 €9,644
02. Nov 18 Buy Minjie Tang Individual 01. Nov 18 01. Nov 18 1,000 €4.38 €4,379
30. Oct 18 Buy Minjie Tang Individual 29. Oct 18 29. Oct 18 2,000 €4.70 €9,408
24. Aug 18 Sell Prudence Investment Management (Hong Kong) Limited Company 21. Aug 18 21. Aug 18 -10,400 €5.98 €-62,227
02. Aug 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 30. Jul 18 30. Jul 18 26,102 €5.87 €153,254
22. Jun 18 Buy Matthews International Capital Management, LLC Company 20. Jun 18 20. Jun 18 71,400 €5.43 €387,362
08. Jun 18 Buy Prudence Investment Management (Hong Kong) Limited Company 05. Jun 18 05. Jun 18 20,000 €6.13 €122,597
15. May 18 Sell Prudence Investment Management (Hong Kong) Limited Company 10. May 18 10. May 18 -9,900 €5.73 €-56,770
10. May 18 Buy Matthews International Capital Management, LLC Company 08. May 18 08. May 18 31,000 €5.77 €178,952
X
Management checks
We assess Shanghai Haohai Biological Technology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Shanghai Haohai Biological Technology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5HB News

Simply Wall St News

5HB Company Info

Description

Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers orthopedics, medical aesthetics and wound care, ophthalmology, anti-adhesion, and homostasis products. It also provides biological reagents and materials, medical sodium hyaluronate, and biochemical and HA series skin care products. In addition, the company engages in the manufacture and sale of intraocular and contact lens, intraocular lens materials, machines, and accessories; and pharmaceutical technology development, and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products; and related technology transfer, and consultation and service activities. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Details
Name: Shanghai Haohai Biological Technology Co., Ltd.
5HB
Exchange: DB
Founded: 2007
HK$1,071,770,145
160,045,300
Website: http://www.3healthcare.com
Address: Shanghai Haohai Biological Technology Co., Ltd.
WenGuang Plaza,
23rd Floor,
Shanghai,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 6826 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong Ltd. HK HKD 30. Apr 2015
DB 5HB Foreign Shares-Foreign Listed Deutsche Boerse AG DE EUR 30. Apr 2015
Number of employees
Current staff
Staff numbers
1,226
Shanghai Haohai Biological Technology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:19
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.